Completed PHASE2 INTERVENTIONAL NCT00193518

Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase II Trial Of Arsenic Trioxide (TRISENOX) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Sponsor: CTI BioPharma

Conditions Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Interventions Arsenic Trioxide

Updated 6 times since 2017 Last updated: May 2, 2011 Started: Apr 30, 2004 Primary completion: Apr 30, 2006 Completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma and is currently completed. CTI BioPharma leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CTI BioPharma
SCRI Development Innovations, LLC

Data source: SCRI Development Innovations, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nashville, United States